CL2015002330A1 - Análogo de insulina novedoso y su uso. - Google Patents
Análogo de insulina novedoso y su uso.Info
- Publication number
- CL2015002330A1 CL2015002330A1 CL2015002330A CL2015002330A CL2015002330A1 CL 2015002330 A1 CL2015002330 A1 CL 2015002330A1 CL 2015002330 A CL2015002330 A CL 2015002330A CL 2015002330 A CL2015002330 A CL 2015002330A CL 2015002330 A1 CL2015002330 A1 CL 2015002330A1
- Authority
- CL
- Chile
- Prior art keywords
- insulin
- conjugate
- innovative
- insulin analogue
- prepare
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN ANÁLOGO DE INSULINA QUE TIENE UN TITULO DE INSULINA REDUCIDO Y UNA AFINIDAD DE UNION DEL RECEPTOR DE INSULINA REDUCIDA EN COMPARACIÓN CON LA FORMA NATURAL CON EL FIN DE INCREMENTAR LA SEMIVIDA DE LA INSULINA EN SANGRE, UN CONJUGADO QUE SE PREPARA ENLAZANDO EL ANÁLOGO DE INSULINA Y UN VEHICULO, UNA FORMULACIÓN DE ACCIÓN PROLONGADA QUE INCLUYE EL CONJUGADO Y UN PROCEDIMIENTO PARA PREPARAR EL CONJUGADO.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130020703 | 2013-02-26 | ||
| KR20130082511 | 2013-07-12 | ||
| KR20140006937 | 2014-01-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002330A1 true CL2015002330A1 (es) | 2015-12-28 |
Family
ID=51428522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002330A CL2015002330A1 (es) | 2013-02-26 | 2015-08-19 | Análogo de insulina novedoso y su uso. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20160008483A1 (es) |
| EP (2) | EP3616727B1 (es) |
| JP (3) | JP6552968B2 (es) |
| KR (2) | KR20140106452A (es) |
| CN (2) | CN114989289A (es) |
| AU (2) | AU2014221531B2 (es) |
| BR (1) | BR112015019985A2 (es) |
| CA (1) | CA2901873C (es) |
| CL (1) | CL2015002330A1 (es) |
| DK (1) | DK2963056T3 (es) |
| ES (2) | ES2868351T3 (es) |
| HK (1) | HK1211944A1 (es) |
| IL (1) | IL240717B (es) |
| MX (1) | MX366400B (es) |
| MY (1) | MY186990A (es) |
| PE (2) | PE20151409A1 (es) |
| PH (1) | PH12015501814B1 (es) |
| PT (1) | PT2963056T (es) |
| RU (1) | RU2676729C2 (es) |
| SA (2) | SA515360933B1 (es) |
| SG (2) | SG10201907106VA (es) |
| TW (3) | TWI708782B (es) |
| UA (1) | UA119533C2 (es) |
| WO (1) | WO2014133324A1 (es) |
| ZA (1) | ZA201507104B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| AR090281A1 (es) * | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
| CA2901873C (en) * | 2013-02-26 | 2022-05-03 | Hanmi Pharm. Co., Ltd. | Novel insulin analog and use thereof |
| EP3098235A4 (en) * | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
| AR100639A1 (es) | 2014-05-29 | 2016-10-19 | Hanmi Pharm Ind Co Ltd | Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
| CN107810202A (zh) * | 2015-02-17 | 2018-03-16 | 韩美药品株式会社 | 长效胰岛素或胰岛素类似物复合物 |
| CN108026143B (zh) | 2015-07-24 | 2022-05-27 | 韩美药品株式会社 | 制备生理活性多肽缀合物的方法 |
| UY36870A (es) | 2015-08-28 | 2017-03-31 | Hanmi Pharm Ind Co Ltd | Análogos de insulina novedosos |
| CN108473548A (zh) * | 2015-09-24 | 2018-08-31 | 韩美药品股份有限公司 | 胰岛素生产方法 |
| US11396534B2 (en) | 2016-09-23 | 2022-07-26 | Hanmi Pharm. Co., Ltd. | Insulin analogs with reduced affinity to insulin receptor and use thereof |
| EP3549950A4 (en) * | 2016-12-05 | 2020-08-19 | Hanmi Pharm. Co., Ltd. | CONJUGATE WITH MITIGATED IMMUNE RESPONSE |
| EP3939605A1 (en) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| JP2020506932A (ja) | 2017-02-03 | 2020-03-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 持続性が増加した生理活性物質の結合体及びその用途 |
| CN110545852B (zh) | 2017-02-07 | 2023-05-26 | 韩美药品株式会社 | 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法 |
| KR101941975B1 (ko) | 2017-03-17 | 2019-01-25 | 고려대학교 산학협력단 | Atpif1을 함유하는 당뇨 치료용 약학조성물 |
| EP3604328A4 (en) * | 2017-03-23 | 2021-01-06 | Hanmi Pharm. Co., Ltd. | REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE |
| JP7377195B2 (ja) | 2017-09-29 | 2023-11-09 | ハンミ ファーマシューティカル カンパニー リミテッド | リンカーとして非ペプチド性重合体結合脂肪酸誘導体化合物を含むタンパク質結合体及びその製造方法 |
| US20200283492A1 (en) * | 2017-09-29 | 2020-09-10 | Hanmi Pharm Co., Ltd. | Long acting protein complex having an enhanced efficiency |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| DK3655006T3 (da) | 2018-06-29 | 2022-02-21 | Akston Biosciences Corp | Ultralangtidsvirkende insulin-Fc-fusionsproteiner og fremgangsmåder til anvendelse deraf |
| KR20210102346A (ko) | 2018-12-11 | 2021-08-19 | 사노피 | 인슐린 콘쥬게이트 |
| BR112021011557A2 (pt) | 2018-12-21 | 2021-09-14 | Hanmi Pharm. Co., Ltd. | Formulação complexa e composição farmacêutica incluindo insulina e glucagon |
| JP2022515229A (ja) | 2018-12-21 | 2022-02-17 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに活性を有する三重活性体と、インスリンとを含む薬学組成物 |
| TW202120536A (zh) * | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| FI4073098T3 (fi) | 2019-12-19 | 2023-11-15 | Akston Biosciences Corp | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| JP2023515247A (ja) | 2020-03-31 | 2023-04-12 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規な免疫活性インターロイキン２アナログ |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| WO2021207599A1 (en) | 2020-04-10 | 2021-10-14 | Akston Biosciences Corporation | Antigen specific immunotherapy for covid-19 fusion proteins and methods of use |
| WO2022017309A1 (zh) * | 2020-07-24 | 2022-01-27 | 江苏晟斯生物制药有限公司 | 胰岛素-Fc融合蛋白及其应用 |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
| WO2023013640A1 (ja) * | 2021-08-02 | 2023-02-09 | Ｓｐｉｂｅｒ株式会社 | 多孔質体及びその製造方法 |
| CN117769616A (zh) * | 2021-08-02 | 2024-03-26 | 丝芭博株式会社 | 合成皮革及其制造方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| DE19735711C2 (de) * | 1997-08-18 | 2001-04-26 | Aventis Pharma Gmbh | Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken |
| US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| JP2008169195A (ja) * | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| JP5688969B2 (ja) * | 2007-07-16 | 2015-03-25 | ノボ・ノルデイスク・エー／エス | プロテアーゼに対して安定しているペグ化インスリンアナログ |
| US8481485B2 (en) * | 2008-12-19 | 2013-07-09 | Indiana University Research And Technology Corporation | Insulin analogs |
| WO2011028813A2 (en) * | 2009-09-01 | 2011-03-10 | Case Western Reserve University | Insulin analogues of enhanced receptor-binding specificity |
| AR081066A1 (es) * | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| KR101324828B1 (ko) * | 2010-06-08 | 2013-11-01 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체 |
| CA2806399A1 (en) * | 2010-07-28 | 2012-02-02 | Smartcells, Inc. | Recombinantly expressed insulin polypeptides and uses thereof |
| UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
| CA2901873C (en) * | 2013-02-26 | 2022-05-03 | Hanmi Pharm. Co., Ltd. | Novel insulin analog and use thereof |
-
2014
- 2014-02-26 CA CA2901873A patent/CA2901873C/en active Active
- 2014-02-26 MX MX2015010471A patent/MX366400B/es active IP Right Grant
- 2014-02-26 BR BR112015019985A patent/BR112015019985A2/pt active Search and Examination
- 2014-02-26 UA UAA201507940A patent/UA119533C2/uk unknown
- 2014-02-26 RU RU2015138536A patent/RU2676729C2/ru active
- 2014-02-26 KR KR1020140022909A patent/KR20140106452A/ko not_active IP Right Cessation
- 2014-02-26 CN CN202210291419.1A patent/CN114989289A/zh active Pending
- 2014-02-26 SG SG10201907106VA patent/SG10201907106VA/en unknown
- 2014-02-26 TW TW106143717A patent/TWI708782B/zh active
- 2014-02-26 ES ES19197388T patent/ES2868351T3/es active Active
- 2014-02-26 ES ES14757629T patent/ES2770776T3/es active Active
- 2014-02-26 PT PT147576292T patent/PT2963056T/pt unknown
- 2014-02-26 PE PE2015001747A patent/PE20151409A1/es active IP Right Grant
- 2014-02-26 TW TW103106674A patent/TWI621626B/zh active
- 2014-02-26 CN CN201480006998.4A patent/CN104995206B/zh active Active
- 2014-02-26 MY MYPI2015001870A patent/MY186990A/en unknown
- 2014-02-26 TW TW108100374A patent/TWI755579B/zh active
- 2014-02-26 PE PE2019001804A patent/PE20191481A1/es unknown
- 2014-02-26 AU AU2014221531A patent/AU2014221531B2/en active Active
- 2014-02-26 EP EP19197388.2A patent/EP3616727B1/en active Active
- 2014-02-26 US US14/769,495 patent/US20160008483A1/en not_active Abandoned
- 2014-02-26 SG SG11201506095TA patent/SG11201506095TA/en unknown
- 2014-02-26 WO PCT/KR2014/001593 patent/WO2014133324A1/ko active Application Filing
- 2014-02-26 EP EP14757629.2A patent/EP2963056B1/en active Active
- 2014-02-26 DK DK14757629.2T patent/DK2963056T3/da active
- 2014-02-26 JP JP2015559199A patent/JP6552968B2/ja active Active
-
2015
- 2015-08-18 PH PH12015501814A patent/PH12015501814B1/en unknown
- 2015-08-19 CL CL2015002330A patent/CL2015002330A1/es unknown
- 2015-08-20 IL IL240717A patent/IL240717B/en active IP Right Grant
- 2015-08-23 SA SA515360933A patent/SA515360933B1/ar unknown
- 2015-08-23 SA SA518400491A patent/SA518400491B1/ar unknown
- 2015-09-25 ZA ZA2015/07104A patent/ZA201507104B/en unknown
- 2015-12-18 HK HK15112526.1A patent/HK1211944A1/xx unknown
-
2018
- 2018-05-18 US US15/983,923 patent/US20180256731A1/en not_active Abandoned
- 2018-11-22 AU AU2018267648A patent/AU2018267648B2/en active Active
-
2019
- 2019-07-03 JP JP2019124525A patent/JP2019187440A/ja active Pending
-
2021
- 2021-08-19 KR KR1020210109688A patent/KR102413691B1/ko active IP Right Grant
- 2021-08-19 JP JP2021133932A patent/JP2021193089A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2015002330A1 (es) | Análogo de insulina novedoso y su uso. | |
| CL2023001911A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| CL2018003754A1 (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo. | |
| CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| BR112015030514A2 (pt) | Composições e métodos para conjugação de anticorpos ativáveis | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| EA201691911A1 (ru) | Быстродействующие композиции инсулина | |
| BR112016002391A2 (pt) | composições tópicas e métodos de uso das mesmas | |
| MX2020000333A (es) | Formulaciones de conjugado anticuerpo anti-egfr-farmaco. | |
| BR112016018891A2 (pt) | anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma | |
| CL2018003527A1 (es) | Conjugados de anticuerpo anti-egfr y fármaco. | |
| DOP2016000176A (es) | Insulina de acción prolongada y uso de la misma | |
| WO2014197849A3 (en) | Anti-c10orf54 antibodies and uses thereof | |
| UY35350A (es) | Pirimidinas condensadas sustituidas con trifluorometilo y su uso | |
| AR094904A1 (es) | Análogos de insulina y su uso | |
| BR112015022587A2 (pt) | formulações de citocina quimérica para entrega ocular | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| BR112015024040A2 (pt) | preparação alergênica | |
| TR201905787T4 (tr) | Liyofilize TAT-NR2B9C formülasyonu. | |
| TWD189563S (zh) | 鼻管組件 | |
| BR112015032200A2 (pt) | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo | |
| ECSP18010616A (es) | Inmunoconjugados de il22 | |
| CL2018003045A1 (es) | Semaglutida en afecciones cardiovasculares. | |
| CL2019002729A1 (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
| CU24453B1 (es) | Anticuerpos anti proteína similar a angiopoyetina 4 |